CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corvus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.65+0.13 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $891.35M
- P/E (TTM)
- –
- Dividend yield
- –
Corvus Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $811.77M | $197.05M |
| Enterprise Value | $596.57M | $106.56M |
| PB Ratio | 3.60 | 2.14 |
| P/TBV Ratio | 3.60 | 2.46 |
Income (trailing twelve months)
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$56.96M | -$21.44M |
| Pretax Income | -$51.79M | -$14.45M |
| Net Income | -$54.13M | -$22.46M |
| EBITDA | -$56.85M | -$16.91M |
| EPS (Diluted) | -$0.61 | -$0.83 |
Returns
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -35.4% | -53.1% |
| Return on Assets (ROA) | -32.9% | -41.0% |
| Return on Invested Capital (ROIC) | -564.1% | -32.0% |
| Return on Capital Employed (ROCE) | -25.2% | -37.8% |
Balance sheet
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $215.20M | $62.42M |
| Net Cash (Debt) | $215.20M | $15.68M |
| Net Cash Per Share | $2.56 | $0.65 |
| Equity (Book Value) | $225.33M | $48.79M |
| Book Value Per Share | $2.68 | $1.36 |
| Tangible Book Value | $225.33M | $23.06M |
| Working Capital | $207.29M | $75.77M |
Financial position
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 16.16 | 3.30 |
| Quick Ratio | 15.74 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$44.53M | -$12.35M |
| Capital Expenditures | -$698.00K | -$1.06M |
| Free Cash Flow | -$45.23M | -$20.28M |
| FCF Per Share | -$0.54 | -$0.41 |
Efficiency
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$1.46M | -$732.08K |
| Employee Count | 37 | 73 |
Dividends and yields
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -6.67% | -21.2% |
| FCF Yield | -5.57% | -7.64% |
Shares
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 84,120,900 | 59,128,900 |
| Shares Change (YoY) | 20.9% | 11.1% |
| Shares Change (QoQ) | 0.04% | 0.54% |
| Float | 58,439,400 | 48,744,500 |
| Shares Held by Insiders | 30.5% | 11.8% |
| Shares Held by Institutions | 84.1% | 59.4% |
Scores
| Measure | Corvus Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 32.58 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Corvus Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.